Human CDR-grafted antibody and antibody fragment thereof
AssigneeKyowa Kirin Co., Ltd.
InventorsKenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
Life of this patent
Estimating the term…
Abstract
A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
Claims5
A method for treating cancer in a patient, said method comprising administering to a patient in need thereof an effective amount of a human CDR-grafted antibody or antibody fragment thereof which reacts with an extracellular region of human CC chemokine receptor 4 (CCR4), wherein the antibody or antibody fragment thereof comprises complementarity determining regions (CDRs) 1-3 of a heavy chain variable region which comprise the amino acid sequences of SEQ ID NOs:
- 1-3, respectively, and CDRs 1-3 of a light chain variable region which comprise the amino acid sequences of SEQ ID NOs:
- 5-7, respectively,
- and wherein cancer cells of the cancer express CCR4.
Dependencies are inferred from the claim text.